Quick Answer
Vera Therapeutics, Inc. reported Long Term Debt of $74.84 million for the year ending 2025.
- Vera Therapeutics, Inc. showed an increase of +47.6% in Long Term Debt from 2024 to 2025.
- This data is from Vera Therapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on February 26, 2026.
- XBRL data for this metric is available from 2020 to 2025 (6 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2022: $4.94 million | Q2 2022: $4.95 million | Q3 2022: $4.97 million | Q1 2023: $24.89 million | Q2 2023: $24.96 million | Q3 2023: $25.04 million | Q1 2024: $50.07 million | Q2 2024: $50.26 million | Q3 2024: $50.47 million | Q1 2025: $50.91 million | Q2 2025: $74.46 million | Q3 2025: $74.65 million.
- Historical annual values: Fiscal year 2025: $74.84 million | Fiscal year 2024: $50.69 million | Fiscal year 2023: $49.88 million | Fiscal year 2022: $24.81 million | Fiscal year 2021: $4.92 million | Fiscal year 2020: $0.00.
- Data sourced from SEC EDGAR public filings as of August 5, 2026.
Last verified: